These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17892497)

  • 1. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective.
    Bevan JS; Newell-Price J; Wass JA; Atkin SL; Bouloux PM; Chapman J; Davis JR; Howlett TA; Randeva HS; Stewart PM; Viswanath A
    Clin Endocrinol (Oxf); 2008 Mar; 68(3):343-9. PubMed ID: 17892497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
    Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly.
    Caron P; Cogne M; Raingeard I; Bex-Bachellerie V; Kuhn JM
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):209-14. PubMed ID: 16430722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
    Lucas T; Astorga R;
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):320-6. PubMed ID: 16918950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
    Caron P; Beckers A; Cullen DR; Goth MI; Gutt B; Laurberg P; Pico AM; Valimaki M; Zgliczynski W
    J Clin Endocrinol Metab; 2002 Jan; 87(1):99-104. PubMed ID: 11788630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).
    An Z; Lei T; Duan L; Hu P; Gou Z; Zhang L; Durand-Gasselin L; Wang N; Wang Y; Gu F;
    BMC Endocr Disord; 2020 May; 20(1):57. PubMed ID: 32366244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lanreotide Autogel for acromegaly: a new addition to the treatment armamentarium.
    Ciccarelli A; Daly A; Beckers A
    Treat Endocrinol; 2004; 3(2):77-81. PubMed ID: 15743103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel).
    Gutt B; Bidlingmaier M; Kretschmar K; Dieterle C; Steffin B; Schopohl J
    Exp Clin Endocrinol Diabetes; 2005 Mar; 113(3):139-44. PubMed ID: 15789272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.
    Chanson P; Borson-Chazot F; Kuhn JM; Blumberg J; Maisonobe P; Delemer B;
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):299-305. PubMed ID: 18248639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single-center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide Autogel in patients with acromegaly previously treated with octreotide.
    Kelly P; Maher KT; Chew SL; Monson JP; Grossman AB; Jenkins PJ
    Endocr Pract; 2010; 16(2):191-7. PubMed ID: 19833584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR.
    Ashwell SG; Bevan JS; Edwards OM; Harris MM; Holmes C; Middleton MA; James RA
    Eur J Endocrinol; 2004 Apr; 150(4):473-80. PubMed ID: 15080776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly.
    Álvarez-Escolá C; Venegas-Moreno EM; García-Arnés JA; Blanco-Carrera C; Marazuela-Azpiroz M; Gálvez-Moreno MÁ; Menéndez-Torre E; Aller-Pardo J; Salinas-Vert I; Resmini E; Torres-Vela EM; Gonzalo-Redondo MÁ; Vílchez-Joya R; de Miguel-Novoa MP; Halperín-Rabinovich I; Páramo-Fernández C; de la Cruz-Sugranyes G; Houchard A; Picó-Alfonso AM;
    Endocrinol Diabetes Nutr (Engl Ed); 2019 May; 66(5):320-329. PubMed ID: 30773338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
    Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Somatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patients].
    Caron P
    Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 3):2S19-24. PubMed ID: 12037499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
    Shimatsu A; Teramoto A; Hizuka N; Kitai K; Ramis J; Chihara K
    Endocr J; 2013; 60(5):651-63. PubMed ID: 23337477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study.
    Caron PJ; Bevan JS; Petersenn S; Houchard A; Sert C; Webb SM;
    Pituitary; 2016 Apr; 19(2):149-57. PubMed ID: 26603536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient satisfaction and preferences of lanreotide Autogel treatment in acromegaly.
    Witek P; Mucha S; Ruchała M
    Endokrynol Pol; 2016; 67(6):572-579. PubMed ID: 28042650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.
    Ronchi CL; Boschetti M; Degli Uberti EC; Mariotti S; Grottoli S; Loli P; Lombardi G; Tamburrano G; Arvigo M; Angeletti G; Boscani PF; Beck-Peccoz P; Arosio M;
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):512-9. PubMed ID: 17555511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study.
    Attanasio R; Lanzi R; Losa M; Valentini F; Grimaldi F; De Menis E; Davì MV; Battista C; Castello R; Cremonini N; Razzore P; Rosato F; Montini M; Cozzi R
    Endocr Pract; 2008 Oct; 14(7):846-55. PubMed ID: 18996812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel.
    Cendros JM; Peraire C; Trocóniz IF; Obach R
    Metabolism; 2005 Oct; 54(10):1276-81. PubMed ID: 16154424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.